Welcome to our dedicated page for OPTIMI HEALTH news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on OPTIMI HEALTH stock.
Optimi Health Corp. (OPTHF) is a leading Health Canada-licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA. The company recently obtained a Drug Establishment Licence (DEL) from Health Canada, confirming compliance with Good Manufacturing Practices (GMP). This allows Optimi to supply MDMA and psilocybin capsules to patients with PTSD and Treatment-Resistant Depression under Australia's Authorized Prescriber Scheme and export to regulated jurisdictions globally. Optimi aims to be the trusted global supplier of safe drug candidates by producing proprietary formulations in its 20,000 square feet facilities in Princeton, BC.
Rhea-AI Summary
Optimi Health Corp. receives an Export Permit from Health Canada to ship MDMA to Tel Aviv University's Institute for Psychedelic Research, marking its first international export. This collaboration signifies a significant milestone for Optimi, showcasing its ability to produce GMP psychedelic pharmaceuticals and support global psychedelic research and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
-
Rhea-AI Summary
Optimi Health Corp. partners with Kwantlen Polytechnic University Applied Genomics Centre to advance mushroom science and research. The project aims to genetically identify psilocybin-containing mushrooms, leveraging Optimi's extensive genetic bank. This collaboration seeks to enhance DNA characterization for clinical trials and medicinal activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.38%
Tags
-
Rhea-AI Summary
Optimi Health Corp. completes in-house production of MDMA Active Pharmaceutical Ingredient (API) from raw materials under Precursor Licence. Three batches tested and validated by third-party laboratory. Company's distinctive advantage with in-house production highlighted. CEO Bill Ciprick emphasizes quality assurance standards and client collaboration. Chief Operations Officer Bryan Safarik reports over 60 grams of MDMA API produced. Company's expertise showcased at upcoming conference in Boston.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
Rhea-AI Summary
Optimi Health Corp. signs a natural psilocybin supply agreement with Mātai Medical Research Institute, marking its first deal in New Zealand. The agreement includes providing GMP Full Spectrum Natural Psilocybin extract to Mātai for the Tū Wairua Project's clinical trial. Optimi recently received COA for three validation batches, showcasing high-quality standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.4%
Tags
-
Rhea-AI Summary
Optimi Health Corp. completes in-house encapsulation of psilocybin extract in 5mg and 10mg dosage formats. Third-party testing confirms compliance with GMP specifications and potency levels. The company progresses towards human consumption release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Optimi Health Corp. announces its role as a Presenting Sponsor at the 4th Annual Psychedelic Therapeutics and Drug Development Conference. CEO Bill Ciprick will speak on the future of GMP psychedelic manufacturing. The event aims to explore the challenges and opportunities in developing psychedelic therapies. Optimi aims to showcase its strength as a top GMP psychedelics manufacturer committed to quality and safety standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.62%
Tags
Rhea-AI Summary
Optimi Health Corp. signs its first international MDMA supply agreement with The Institute for Psychedelic Research at Tel Aviv University, marking its entry into the Israeli market. The collaboration aims to support research on the effects of MDMA on alcohol addiction in animal models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.25%
Tags
-
Rhea-AI Summary
Optimi Health Corp. closed the first tranche of a private placement, led by co-founders JJ Wilson and Dane Stevens, raising CAD$555,010. The company issued 1,850,033 units at CAD$0.30 per unit. Each unit consists of a common share and a warrant. The proceeds will be used to obtain a Drug Establishment License, facilitate commercialization, and for general working capital. Founders committed to a one-year lock-up period for their shares, showing dedication to commercializing the business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.55%
Tags
-
Rhea-AI Summary
Optimi Health Corp. congratulates Lykos Therapeutics on FDA's acceptance of NDA for PTSD therapy. Optimi showcases GMP MDMA production process. FDA's priority review highlights the potential breakthrough in mental healthcare. Optimi aligns with Lykos protocol for MDMA encapsulation. Optimi emphasizes commitment to quality assurance and transparency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
Rhea-AI Summary
Optimi Health Corp. announces a non-brokered private placement of up to 5,000,000 units at CAD$0.30 per unit, with gross proceeds of up to CAD$1,500,000. The company intends to use the net proceeds to obtain its Drug Establishment License, commercialization, and for general working capital. Insiders of the company may participate in the offering for up to $605,000. The issuance of units to insiders will be considered a 'related party transaction'. All securities issued under the offering will be subject to a hold period expiring 4 months and 1 day after issuance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
FAQ
What is the current stock price of OPTIMI HEALTH (OPTHF)?
The current stock price of OPTIMI HEALTH (OPTHF) is $0.15027 as of January 29, 2025.
What is the market cap of OPTIMI HEALTH (OPTHF)?
The market cap of OPTIMI HEALTH (OPTHF) is approximately 14.3M.
What is Optimi Health Corp. specialized in?
Optimi is a Health Canada-licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances like botanical psilocybin and MDMA.
What recent milestone did Optimi achieve?
Optimi obtained a Drug Establishment Licence (DEL) from Health Canada, affirming its compliance with Good Manufacturing Practices (GMP) to supply MDMA and psilocybin capsules for patients.
What is Optimi's goal in the pharmaceutical industry?
Optimi aims to be the top trusted supplier of safe drug candidates globally by producing proprietary formulations in its 20,000 square feet facilities in Princeton, BC.
Where is Optimi's manufacturing facility located?
Optimi's manufacturing facilities totaling 20,000 square feet are located in Princeton, British Columbia.
What licenses does Optimi hold?
Optimi holds a Controlled Drugs and Substances Dealer's Licence and a Drug Establishment Licence (DEL), enabling the production of GMP-grade products and APIs.
How does Optimi plan to support global psychedelic research?
Optimi has completed its first international shipment of MDMA to Israel, supporting global research and innovation in the psychedelic field.
What is Optimi's key achievement in terms of export?
Optimi received the necessary Export Permit from Health Canada, confirming its ability to export controlled substances internationally.
What services does Oak Hill Financial Inc. provide to Optimi?
Oak Hill Financial Inc. provides comprehensive investor relations, business, and capital markets advisory services to Optimi at a rate of CDN$12,000 per month.
How does Optimi plan to expand its shareholder base?
Optimi aims to engage new investors and communicate its corporate milestones effectively through partnerships like Oak Hill Financial Inc.
What makes Optimi unique in the pharmaceutical industry?
Optimi's unique capabilities lie in producing scalable psychedelic formulations for transformational human experiences while meeting the highest quality and safety standards.
OPTIMI HEALTH CORP
OTC:OPTHF
OPTHF Rankings
OPTHF Stock Data
14.35M
58.12M
16.52%
0.05%
Drug Manufacturers - Specialty & Generic
Healthcare
United States of America
Garibaldi Highlands